Hanmi Pharmaceutical Signs Fabry Disease Drug Licensing Deal With BioMarin Worth Up to USD 237.5 Million

Bitget2026/10/29 22:48

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Hanmi Pharmaceutical signed a USD 237.5 million licensing agreement with BioMarin Pharmaceutical for Fabry disease treatment LA-GLA on Oct. 29, 2026.
Terms include USD 35 million upfront, USD 202.5 million in milestone payments and royalties on annual net sales.
BioMarin receives exclusive global rights to research, develop, manufacture and commercialize the treatment through the royalty period.
South Korean approval and commercialization rights remain with Hanmi and Green Cross.
The treatment, jointly developed with Green Cross, is undergoing Phase 1/2 clinical trials in South Korea and abroad.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hanmi Pharmaceutical Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261030800002), on October 30, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Hanmi Pharmaceutical Signs Fabry Disease Drug Licensing Deal With BioMarin Worth Up to USD 237.5 Million

You may also like

Crypto prices